Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 29Breast Neoplasms 10Neoplasms 2Stage II Prostate Adenocarcinoma 1Salivary Gland Neoplasms 1Prostatectomy 1Prostate Cancer Metastatic Disease 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Metastatic Castration-resistant Prostate Cancer 1Highly Endocrine Responsive Operable Breast Cancer 1Cardiovascular Diseases 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Gonadotropin-Releasing Hormone × Clear all
NCT00587431 2023-11-07

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
102 enrolled 8 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00586898 2016-03-25

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
36 enrolled 6 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡